ReviewReviews in endocrine & metabolic disorders2001
Treatment of postmenopausal osteoporosis: an evidence-based approach.
Review in Reviews in endocrine & metabolic disorders, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 7 citations in OpenAlex.
- Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2014Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
I have outlined several therapeutic approaches to the prevention and treatment of PMO. As we enter the 21st century it is certain that even more options will become available for the physician. But, several issues are still unresolved and will require more extensive investigation. These include the following: 1. Employing intermittent (weekly or monthly) oral or intravenous bisphosphonate therapy to treat PMO. 2. Using combination therapy such as an anabolic agent and an anti-resorptive to further reduce fracture risk and enhance BMD. 3. Understanding the various factors which contribute to fracture risk reduction independent of changes in bone mineral density. 4. Defining the role of biochemical markers in predicting fracture risk reduction. 5. Designing new SERMS which combine the best properties of estrogen and estrogen-like products while avoiding significant side effects. What is certain, is that there are now cost effective treatments for this disease. It remains up to the practicing physician to select, based on the existing evidence, treatments most appropriate for the individual patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.